Belite Bio (BLTE) Corporate presentation summary

Executive leadership and expertise

• Leadership team includes experienced executives with backgrounds in biotech, ophthalmology, and capital markets.

• Key members have led multiple drug developments and clinical studies in retinal diseases.

Pipeline and market opportunity

• Tinlarebant is in late-stage clinical development for Stargardt disease (STGD1) and geographic atrophy (GA).

• No FDA-approved treatments exist for STGD1 or orally administered treatments for GA.

• Tinlarebant has received multiple regulatory designations, including Breakthrough Therapy and Orphan Drug status.

• Estimated 53,000 STGD1 patients in the US and 973,000 GA patients, with a global GA population of about 5 million.

Mechanism of action and disease rationale

• Tinlarebant is a once-daily oral tablet that binds serum RBP4 to reduce retinol delivery to the eye.

• Reducing retinol delivery is expected to lower toxic bisretinoid accumulation, slowing retinal degeneration.

• STGD1 and GA share similar retinal pathology, supporting a common therapeutic approach.